BioCentury
ARTICLE | Company News

MorphoSys, Novartis deal to run through 2017

July 7, 2009 1:04 AM UTC

MorphoSys AG (Xetra:MOR) said a clause in a 2007 antibody deal allowing Novartis AG (NYSE:NVS; SIX:NOVN) to terminate the collaboration after seven years was removed because MorphoSys met predetermined technology improvement goals, including the release of its HuCAL Platinum antibody library. The deal will run until 2017, with $600 million in financing committed to MorphoSys (See BioCentury, Dec. 24, 2007). ...